Jun 12, 2019 / 08:20PM GMT
Terence C. Flynn - Goldman Sachs Group Inc., Research Division - MD
Okay. Great. I think we're going to get started. Thanks so much for joining us for the afternoon session. I'm Terence Flynn, the biopharma analyst here at Goldman Sachs. We're very pleased to have Eli Lilly with us this afternoon. Joining us from the company is Josh Smiley, CFO. Josh, thanks very much for taking the time.
Joshua L. Smiley - Eli Lilly and Company - Senior VP & CFO
Thanks for having us.
Questions and Answers:
Terence C. Flynn - Goldman Sachs Group Inc., Research Division - MDMaybe just to get started, big picture, given your background and experience, would just kind of love to hear your thoughts on this question about broader industry consolidation. There's been consolidation in the payer-provider side now over the last couple of years. We saw another large transaction earlier this year in the biopharma space. So do you think this is the start of a trend here in the biopharma space in response to kind of the payer-provider